Eli Lilly (LLY) Announced Positive Results From its Phase 3 ATTAIN-1 Trial of Orforglipron

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) announced positive results from its Phase 3 ATTAIN-1 trial of Orforglipron, which is an oral drug for overweight adults without diabetes.

The trial, which lasted 72 weeks and included 3,127 participants, showed significant weight loss compared to the placebo. The highest dose administered during the trial was 36 mg daily, which led to an average weight loss of 12.4%. Over half of the participants on this dose lost at least 10% of their body weight. Moreover, the drug also improved cardiovascular risk markers like cholesterol and blood pressure.

Management noted that the safety profile of Orforglipron matched expectations for its class of drugs, and discontinuation due to side effects was low. The company plans to submit the drug for regulatory approval by the end of the year and aims for a global launch.

Eli Lilly and Company (NYSE:LLY) is an international pharmaceutical company that discovers, develops, and markets medicines across various health areas.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.